Literature DB >> 6277792

Protection against feline leukemia by vaccination with a subunit vaccine.

M G Lewis, L E Mathes, R G Olsen.   

Abstract

An effective vaccine against feline leukemia virus infection has been developed by the collection and concentration of tissue culture medium harvested from a tumor cell line. Lymphoid cells were grown to near saturation density in a normal growth medium and then transferred to a serum-free medium. The serum-free medium was collected, concentrated, and evaluated for its vaccine potential. Cats receiving the vaccine emulsified in complete Freund adjuvant developed high antiviral and antitumor titers and were protected (81%) against virus challenge. Cats receiving the vaccine without an adjuvant developed lower antibody levels and lower protection (53%) from viremia. Age-matched and litter-matched controls developed no antibody to test antigens before the challenge, and 100% became persistently viremic after the challenge. Vaccination with the soluble tumor cell antigen vaccine proved successful in preventing the induction of feline leukemia virus infection.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6277792      PMCID: PMC350952          DOI: 10.1128/iai.34.3.888-894.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A.

Authors:  S W Kessler
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

2.  Influence of culture conditions of growth of FL-74 cells and feline oncornavirus cell membrane associated antigen production.

Authors:  R G Olsen; G E Milo; J P Schaller; L E Mathes; L Heding; D S Yohn
Journal:  In Vitro       Date:  1976-01

3.  Detection of the feline leukemia virus and other mammalian oncornaviruses by immunofluorescence.

Authors:  W D Hardy; Y Hirshaut; P Hess
Journal:  Bibl Haematol       Date:  1973

4.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

5.  Feline leukemia-virus infection of kittens: mortality associated with atrophy of the thymus and lymphoid depletion.

Authors:  L J Anderson; W F Jarrett; O Jarrett; H M Laird
Journal:  J Natl Cancer Inst       Date:  1971-10       Impact factor: 13.506

6.  Replication of cat leukemia virus in cell suspension cultures.

Authors:  G H Theilen; T G Kawakami; J D Rush; R J Munn
Journal:  Nature       Date:  1969-05-10       Impact factor: 49.962

7.  Antibody to feline oncornavirus-associated cell membrane antigen in neonatal cats.

Authors:  M Essex; G Klein; S P Snyder; J B Harrold
Journal:  Int J Cancer       Date:  1971-11-15       Impact factor: 7.396

8.  Biology of feline leukemia virus in the natural environment.

Authors:  W D Hardy; P W Hess; E G MacEwen; A J McClelland; E E Zuckerman; M Essex; S M Cotter; O Jarrett
Journal:  Cancer Res       Date:  1976-02       Impact factor: 12.701

9.  Determination of subgroup-specific feline oncornavirus-neutralizing antibody.

Authors:  J P Schaller; R G Olsen
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

10.  Vaccination against feline leukaemia virus using a cell membrane antigen system.

Authors:  W Jarrett; O Jarrett; L Mackey; H Laird; C Hood; D Hay
Journal:  Int J Cancer       Date:  1975-07-15       Impact factor: 7.396

View more
  16 in total

Review 1.  Feline leukemia virus: current status of the feline induced immune depression and immunoprevention.

Authors:  R G Olsen; M G Lewis; L J Lafrado; L E Mathes; K Haffer; R Sharpee
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

2.  Saliva as a source of feline leukemia virus antigen for diagnosis of disease.

Authors:  M G Lewis; K A Wright; L J Lafrado; P J Shanker; N E Palumbo; E D Lemoine; R G Olsen
Journal:  J Clin Microbiol       Date:  1987-07       Impact factor: 5.948

3.  Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective.

Authors:  N C Pedersen; L Johnson; D Birch; G H Theilen
Journal:  Vet Immunol Immunopathol       Date:  1986-02       Impact factor: 2.046

4.  Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors.

Authors:  L Hanlon; D Argyle; D Bain; L Nicolson; S Dunham; M C Golder; M McDonald; C McGillivray; O Jarrett; J C Neil; D E Onions
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody.

Authors:  W G Robey; L O Arthur; T J Matthews; A Langlois; T D Copeland; N W Lerche; S Oroszlan; D P Bolognesi; R V Gilden; P J Fischinger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

6.  Recombinant feline herpesviruses expressing feline leukemia virus envelope and gag proteins.

Authors:  G E Cole; S Stacy-Phipps; J H Nunberg
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

7.  Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.

Authors:  L O Arthur; J W Bess; D J Waters; S W Pyle; J C Kelliher; P L Nara; K Krohn; W G Robey; A J Langlois; R C Gallo
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

8.  Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine.

Authors:  L O Arthur; S W Pyle; P L Nara; J W Bess; M A Gonda; J C Kelliher; R V Gilden; W G Robey; D P Bolognesi; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

9.  The development of an AIDS vaccine: progress and promise.

Authors:  A S Fauci; P J Fischinger
Journal:  Public Health Rep       Date:  1988 May-Jun       Impact factor: 2.792

10.  Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies.

Authors:  P L Nara; W G Robey; S W Pyle; W C Hatch; N M Dunlop; J W Bess; J C Kelliher; L O Arthur; P J Fischinger
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.